PDS Biotechnology Corp Files 2025 10-K/A: Key Details for Investors

PDS Biotechnology Corp (Nasdaq: PDSB) has filed its amended Annual Report on Form 10-K/A for the fiscal year ended December 31, 2025. This amendment, filed on April 28, 2026, provides comprehensive updates on corporate governance, executive compensation, equity ownership, and other critical disclosures. Below is an in-depth analysis of the filing, highlighting the most significant points and potential implications for investors.

Key Highlights from the Amended Filing

• Corporate Information:
  • Headquarters: 303A College Road East, Princeton, NJ 08540
  • Common Stock trading symbol: PDSB
  • Exchange: Nasdaq Capital Market
  • Outstanding Shares as of March 23, 2026: 55,815,653
  • Public Float as of June 30, 2025: \$60,145,221
• Nature of Amendment:
  • The amendment was filed to include information required under Items 10-14 of Part III of Form 10-K, covering Directors, Executive Officers and Corporate Governance, Executive Compensation, Security Ownership, Certain Relationships and Related Transactions, and Principal Accountant Fees and Services.
  • Important: No changes were made to previously reported financial results or events after the original filing date (March 30, 2026).

1. Corporate Governance and Board Structure

• Board Composition:
  • Directors are divided into three classes with staggered terms expiring in 2026, 2027, and 2028.
  • Key directors: Stephen Glover, Gregory Freitag (Audit Committee Chair), Kamil Ali-Jackson, Ilian Iliev, Frank Bedu-Addo (CEO).
  • All directors meet Nasdaq independence standards except for Dr. Bedu-Addo (CEO).
• Board Committees:
  • Audit Committee: Oversees financial reporting, internal controls, compliance, and approves related-party transactions. All members are independent; Mr. Freitag is the designated financial expert. Held four meetings in 2025.
  • Compensation Committee: Oversees executive and director compensation, incentive plans, and annual performance reviews. Also held four meetings in 2025.
  • Nominating and Corporate Governance Committee: Develops governance principles, board evaluations, and director qualifications.
• Governance Practices:
  • Code of Conduct applies to all employees, officers, and directors. Any waivers or amendments are disclosed online within four business days.
  • Anti-Hedging/Anti-Pledging Policy prohibits directors and officers from pledging, hedging, or holding company securities in margin accounts without approval.
• Section 16(a) Compliance:
  • All directors and officers filed required forms timely in 2025, except for one late Form 4 for several executives due to administrative oversights.

2. Executive Compensation

• Compensation Philosophy:
  • Due to the long cycle of drug development, traditional financial metrics are less relevant; performance is measured by R&D progress, business initiatives (including financings), and increasing shareholder value.
  • Annual goals set by leadership and approved by the board; performance is reviewed annually for compensation adjustments.
• Named Executive Officers (NEOs) and 2025 Compensation:
  • Frank Bedu-Addo, Ph.D. (CEO):
    • Base Salary: \$615,322
    • Target Bonus: Up to 55% of base salary
    • Received a grant of 150,000 stock options on June 12, 2025
  • Kirk Shepard, M.D. (Chief Medical Officer):
    • Base Salary: \$490,000
    • Target Bonus: Up to 45% of base salary
    • Received 150,000 stock options on June 12, 2025
  • Stephan Toutain (Chief Operating Officer):
    • Base Salary: Not explicitly stated in summary, but consistent with peer NEOs
    • Target Bonus: Up to 40% of base salary
    • Received 150,000 stock options on June 12, 2025
• Equity Awards:
  • Stock options are granted on an infrequent, non-predictable basis, and not timed with the release of material non-public information.
  • Grants on June 12, 2025, were made close to a material disclosure, but the company asserts no timing manipulation. The closing market price immediately before and after the grant increased by 6.55%, which may be scrutinized by investors for potential alignment with shareholder interests.
• 2025 Annual Cash Bonuses:
  • No discretionary annual cash bonuses were paid to NEOs for 2025. This was a decision aimed at conserving cash for operations and strategic priorities, not due to individual performance shortfalls.
• Outstanding Equity Awards:
  • As of December 31, 2025, NEOs held significant unexercised options, but no outstanding stock awards (RSUs).

3. Equity Compensation Plan Information

• Equity Compensation Plans Approved by Shareholders:
  • Outstanding Options: 4,992,224
  • Outstanding RSUs: 800,000
• Non-Shareholder Approved Plans:
  • Outstanding Options: 942,800
  • Weighted-average exercise price: \$4.58

4. Board and Executive Stock Ownership

• As of the filing date, no shareholder or group is reported to own more than 5% of the company’s stock. This may indicate a widely held ownership structure, which can have both positive (lower risk of hostile takeover) and negative (potential lack of a strategic anchor investor) implications.
• Directors and Officers: All ownership details are reported in line with SEC beneficial ownership rules, including options exercisable within 60 days.

5. Additional Noteworthy Governance and Policy Details

• Stockholder Communications: No formal process, but CEO Frank Bedu-Addo acts as conduit for all board communications from shareholders.
• Audit, Compensation, and Governance Committee Charters: All charters are published on the company website for transparency.

Potentially Price-Sensitive or Shareholder-Relevant Items

• Compensation Policy Shift: The decision to withhold annual cash bonuses for executive officers in 2025 due to the company’s focus on conserving cash could signal financial prudence or cash constraints, which may impact investor confidence, depending on interpretation.
• Equity Grants Timing: The timing of substantial executive option grants near the release of material information, coupled with a 6.55% share price increase, may be scrutinized by the market for alignment with shareholder interests and executive incentives.
• No 5% Shareholders: The absence of any controlling shareholders or institutional anchors is notable for investors concerned about future capital raises, governance, or strategic direction.

Conclusion

PDS Biotechnology’s 2025 10-K/A provides detailed insight into the company’s governance, executive compensation, and equity structures. While no restatement of financials or new material events were disclosed, the company’s focus on cash conservation, significant option grants to executives, and lack of a dominant shareholder are all relevant for investors assessing future prospects, dilution risk, and the alignment between management and shareholder interests.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full SEC filing and consult with financial advisors before making any investment decisions. The information has been summarized faithfully from the company’s public filings, but accuracy or completeness cannot be guaranteed.

View PDS Biotechnology Corp Historical chart here